MINI FUTURE SHORT - NOVO-NORDISK B | Market Closed - Euronext Paris 02:31:52 2024-06-04 am EDT | ||
| 3.545 EUR | +1.58% |
|
| Current month | -0.57% | ||
| 1 month | -22.27% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 24-06-04 | 3.545 | +1.58% |
| 24-06-03 | 3.49 | -0.57% |
| 24-05-31 | 3.51 | -2.23% |
| 24-05-30 | 3.59 | -1.64% |
| 24-05-29 | 3.65 | +1.67% |
Real-time Euronext Paris
Last update June 04, 2024 at 02:31 am EDT
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| RI4NB | |
| ISIN | NLBNPNL2NSA5 |
| Date issued | 2024-02-19 |
| Strike | 1,184 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.55 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 5.005 € |
|---|---|
| Lowest since issue | 3.235 € |
| Spread | 0.11 € |
| Spread % | 3.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
923.9
DKK
Average target price
917.2
DKK
Spread / Average Target
-0.72%
- Stock Market
- Certificates
- RI4NB Certificat
